Article

SOLX creates GMS certification program

Boston-SOLX, the glaucoma division of OccuLogix Inc., has begun an international program to train and certify ophthalmologists in Europe and the Middle East in surgical implantation procedures using the company’s Gold Micro-Shunt (GMS) products to treat patients with glaucoma.

Boston-SOLX, the glaucoma division of OccuLogix Inc., has begun an international program to train and certify ophthalmologists in Europe and the Middle East in surgical implantation procedures using the company’s Gold Micro-Shunt (GMS) products to treat patients with glaucoma.

The company held an educational symposium before the recent American Academy of Ophthalmology annual meeting in Las Vegas and is offering additional didactic training sessions at various locations around the world (see http://www.solx.com for more information). Surgical certification is conducted at individual surgery practices.

SOLX launched the GMS line at the European Society of Cataract and Refractive Surgeons meeting in London in September. FDA clinical studies are under way at 10 centers worldwide.

GMS products are 24-karat gold, biocompatible, ultra-thin implants approximately half the thickness of a human hair. Unlike tubular drainage devices, GMS devices are flat plates containing numerous micro-tubular channels that create a bridge between the anterior chamber and suprachoroidal space. They use the eye’s natural pressure differential to maximize uveoscleral outflow and reduce IOP without a bleb. The technology is implanted through one 4-mm microincision and rests permanently in the suprachoroidal space.

“We believe that SOLX GMS products offer a significant advancement in the treatment of glaucoma by eliminating blebs and bleb-related complications,” said Doug Adams, president, OccuLogix glaucoma division.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) The Residency Report: Clinical insights from the iStent infinite trial
(Image credit: Ophthalmology Times) ASCRS 2025: Amar Shah, MD, on why hyperosmolar tear film before and after cataract surgery matters
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.